首个抗 PD-L1 药物获批用于 NSCLC。
First Anti-PD-L1 Drug Approved for NSCLC.
出版信息
Cancer Discov. 2016 Dec;6(12):OF1. doi: 10.1158/2159-8290.CD-NB2016-143. Epub 2016 Nov 14.
Abstract
Based on the results of two large international randomized trials, the FDA approved the anti-PD-L1 agent atezolizumab in October. It is the first PD-L1 inhibitor approved for use in patients with metastatic non-small cell lung cancer that has advanced in spite of treatment with platinum-based chemotherapy.
摘要
基于两项大型国际随机试验的结果，FDA 于 10 月批准了抗 PD-L1 药物阿替利珠单抗。这是首个获批用于治疗转移性非小细胞肺癌的 PD-L1 抑制剂，此类患者在接受铂类化疗后病情仍进展。
Zotero 插件